Scholarlink

<p>Sensitive and scalable biomarkers are critical for tracking progression during the prodromal phase of Parkinson’s disease, particularly in idiopathic REM sleep behavior disorder (iRBD). We evaluated the Roche PD Mobile Application version 2, a smartphone-based platform, in 51 individuals with polysomnography-confirmed iRBD, 89 patients with early Parkinson’s disease, and 22 healthy controls over 12 months. Participants completed daily active tasks generating validated digital summary measures. Adherence was high (73%). Baseline digital bradykinesia scores discriminated between groups (<i>p</i> &lt; 0.001) and were higher in phenoconverters versus non-converters (<i>p</i> = 0.003; Cohen’s d = 1.10). Over 50 weeks, bradykinesia (Cohen’s d = 0.50) and speech (Cohen’s d = 0.79) scores worsened significantly. Sample size modeling showed that digital bradykinesia required 132 participants per arm to detect a 50% treatment effect, fewer than the best-performing clinical measure. These findings support digital bradykinesia as a sensitive endpoint for prodromal Parkinson’s disease trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Smartphone-derived digital motor measures to monitor progression in idiopathic REM sleep behavior disorder

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月27日

查看全文
  • Sarah Bouhadoun,
  • Kirsten I. Taylor,
  • Stefan Lambrecht,
  • Werner L. Popp,
  • Damian Kwasny,
  • Michael Lindemann,
  • Martin J. McKeown,
  • Antoine Duquette,
  • Nicolas Jodoin,
  • Valerie Soland,
  • Nicolas Dupré,
  • Julius Anang,
  • Barbara S. Connolly,
  • Kerrie Schoffer,
  • David A. Grimes,
  • Ronald B. Postuma

摘要

Sensitive and scalable biomarkers are critical for tracking progression during the prodromal phase of Parkinson’s disease, particularly in idiopathic REM sleep behavior disorder (iRBD). We evaluated the Roche PD Mobile Application version 2, a smartphone-based platform, in 51 individuals with polysomnography-confirmed iRBD, 89 patients with early Parkinson’s disease, and 22 healthy controls over 12 months. Participants completed daily active tasks generating validated digital summary measures. Adherence was high (73%). Baseline digital bradykinesia scores discriminated between groups (p < 0.001) and were higher in phenoconverters versus non-converters (p = 0.003; Cohen’s d = 1.10). Over 50 weeks, bradykinesia (Cohen’s d = 0.50) and speech (Cohen’s d = 0.79) scores worsened significantly. Sample size modeling showed that digital bradykinesia required 132 participants per arm to detect a 50% treatment effect, fewer than the best-performing clinical measure. These findings support digital bradykinesia as a sensitive endpoint for prodromal Parkinson’s disease trials.